Showing 4171-4180 of 9773 results for "".
- Hyphens Pharma Licenses Winlevi for 10 ASEAN Countries from Cosmo Pharmaceuticalshttps://practicaldermatology.com/news/hyphens-pharma-licenses-winlevi-for-10-asean-countries-from-cosmo-pharmaceuticals/2461475/Hyphens Pharma International Limited’s subsidiary Hyphens Pharma Pte. Ltd. has entered into exclusive license and supply agreements with Cassiopea S.p.A to develop and commercialize Winlevi (clascoterone) cream 1% and all future product extensions and/or improvemenst in the treat
- FDA Clears the Accure Laser System for the Treatment of Mild to Severe Inflammatory Acne Vulgarishttps://practicaldermatology.com/news/fda-clears-the-accure-laser-system-for-the-treatment-of-mild-to-severe-inflammatory-acne-vulgaris/2461439/The FDA has cleared Accure Acne Inc's Accure Laser System to treat mild to severe inflammatory acne vulgaris. The Accure Laser System builds upon the unique selectivity of the 1726nm laser wavelength, adding proprietary technology to precisely control thermal gradient depth. This technology b
- Nu Skin Launches ageLOC LumiSpa iOhttps://practicaldermatology.com/news/nu-skin-launches-ageloc-lumispa-io/2461437/Nu Skin Enterprises is introducing ageLOC LumiSpa iO system, a smart skin treatment and cleansing device with a connected, immersive experience. Featuring Nu Skin's patented micropulse technology, the new ageLOC LumiSpa iO system offers customized treatment options, intel
- DermTech, Sonora Quest Laboratories Join Forces Expand Access to Melanoma Detection Test in Arizonahttps://practicaldermatology.com/news/dermtech-sonora-quest-laboratories-join-forces-expand-access-to-melanoma-detection-test-in-arizona/2461434/Sonora Quest is the exclusive laboratory offering the DermTech Melanoma Test for all of Arizona. The DermTech Melanoma Test uses a non-invasive Smart Sticker to lift skin cells from the surface of a patient’s skin to be tested for select genomic markers associated with melanoma. I
- Supergoop! Founder & CEO Named Ernst & Young LLP’s Entrepreneurs of the Year for 2022https://practicaldermatology.com/news/supergoop-founder-ceo-named-ernst-young-llps-entrepreneurs-of-the-year-for-2022/2461430/Holly Thaggard and Amanda Baldwin of Supergoop! are Ernst & Young LLP’s Entrepreneurs of the Year for 2022. The Entrepreneur of the Year program honors and elevates entrepreneurs who think big and act boldly to change our world for nearly four decades.
- Revance Shares Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessmenthttps://practicaldermatology.com/news/revance-shares-two-publications-in-the-aesthetic-surgery-journal-that-advance-glabellar-line-injection-technique-and-assessment/2461425/Two peer-reviewed articles in the Aesthetic Surgery Journal, the official journal of The Aesthetic Society, highlight the nuances of glabellar line injection technique and aim to improve patient outcomes, irrespective of the neuromodulator used. The
- High Rates of Skin Conditions Seen Among Urban-living Indigenous Kids in High-Income Countrieshttps://practicaldermatology.com/news/high-rates-of-skin-conditions-seen-among-urban-living-indigenous-kids-in-high-income-countries/2461421/Many urban-living Indigenous children and young people in high-income countries are burdened with atopic dermatitis and bacterial skin infections, according to Aasystematic analysis in Pediatric Dermatology. Invest
- IFPA Launches All the Colors We Are to Call Attention to Diversity in Psoriatic Diseaseshttps://practicaldermatology.com/news/ifpa-launches-all-the-colors-we-are-to-call-attention-to-diversity-in-psoriatic-diseases/2461419/IFPA is launching a new image library that raises awareness of diversity in psoriatic disease. IFPA is the global organization representing all people with psoriatic disease,. Go to any image database, and type “psoriasis” in the search bar. The results? Invariably
- EMA Accepts Filing of MAA for Almirall's Lebrikizumab in ADhttps://practicaldermatology.com/news/ema-accepts-filing-of-maa-for-almiralls-lebrikizumab-in-ad/2461408/The European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for Almirall’s lebrikizumab for the treatment of moderate to severe atopic dermatitis. Lebrikizumab is a novel, investigational, monoclonal antibod
- Almirall’s New Psoriasis Campaign Sheds Light on How the Disease Affects Mental Health and Wellbeinghttps://practicaldermatology.com/news/almiralls-new-psoriasis-campaign-sheds-light-on-how-the-disease-affects-mental-health-and-wellbeing/2461407/Almirall and the International Federation of Psoriasis Association are launching the second edition of the "Shedding Light on Psoriasis" campaign for World Psoriasis Day 2022. Shedding Light on Psoriasis